Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Capecitabine

FDA-approved product (tablet, oral), marketed as Capecitabine, Xeloda.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Capecitabine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Actinic keratosis
  • Adenocarcinoma
  • Basal cell carcinoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Colon carcinoma
  • Colonic neoplasm
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal carcinoma
  • Colorectal neoplasm
  • Gastric adenocarcinoma
  • Gastric cancer
  • Gastric carcinoma
  • and 6 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Pyrimidine analogues
FDA pharmacologic class
Nucleoside Metabolic Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Capecitabine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Capecitabine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer

    NCT06157216 · start 2023-10-01

    Registered record
    Registry ID
    NCT06157216
    Conditions
    Stage II-III Gastric Cancer
    Interventions
    MRD-guided therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2023-10-01
    Completion
    2029-04-01
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage II-III Gastric Cancer
    InterventionMRD-guided therapy
    PhaseNot applicable
    Registry statusActive not recruiting

  • Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks

    NCT05212454 · start 2023-03-15

    Registered record
    Registry ID
    NCT05212454
    Conditions
    Breast Cancer; Chemotherapy Effect
    Interventions
    Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-03-15
    Completion
    2029-12
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Chemotherapy Effect
    InterventionCapecitabine
    PhasePhase 3
    Registry statusRecruiting

  • Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)

    NCT05534087 · start 2022-12-15

    Registered record
    Registry ID
    NCT05534087
    Conditions
    Colon Cancer
    Interventions
    mFOLFIRINOX-FOLFIRI intensified chemotherapy; FOLFOX or CAPOX adjuvant chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-12-15
    Completion
    2030-09-30
    Enrolment
    236

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColon Cancer
    InterventionmFOLFIRINOX-FOLFIRI intensified chemotherapy; FOLFOX or CAPOX adjuvant chemotherapy
    PhasePhase 3
    Registry statusRecruiting

  • Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

    NCT05549466 · start 2022-10-08

    Registered record
    Registry ID
    NCT05549466
    Conditions
    Nasopharyngeal Carcinoma
    Interventions
    Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel); Apatinib, Camrelizumab; Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel); Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-10-08
    Completion
    2025-09-20
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNasopharyngeal Carcinoma
    InterventionApatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel); Apatinib, Camrelizumab; Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel); Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
    PhasePhase 2
    Registry statusUnknown

  • Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer

    NCT05358704 · start 2022-05-13

    Registered record
    Registry ID
    NCT05358704
    Conditions
    Cancer of Rectum
    Interventions
    combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Suspended
    Start
    2022-05-13
    Completion
    2028-01-30
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer of Rectum
    Interventioncombination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)
    PhasePhase 2
    Registry statusSuspended

  • Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients

    NCT05680194 · start 2022-04-01

    Registered record
    Registry ID
    NCT05680194
    Conditions
    Breast Cancer Female
    Interventions
    operation; Bisphosphonate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-04-01
    Completion
    2025-12-01
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Female
    Interventionoperation; Bisphosphonate
    PhaseNot recorded
    Registry statusUnknown

  • A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

    NCT05009069 · start 2022-03-18

    Registered record
    Registry ID
    NCT05009069
    Conditions
    Rectal Neoplasms; Rectal Cancer
    Interventions
    Radiotherapy; Capecitabine; Fluorouracil; Atezolizumab; Tiragolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-03-18
    Completion
    2026-11-10
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRectal Neoplasms; Rectal Cancer
    InterventionRadiotherapy; Capecitabine; Fluorouracil; Atezolizumab +1 more
    PhasePhase 2
    Registry statusActive not recruiting

  • PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer

    NCT04833387 · start 2021-01-01

    Registered record
    Registry ID
    NCT04833387
    Conditions
    Colorectal Carcinoma
    Interventions
    PD-1 antibody
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-01-01
    Completion
    2026-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Carcinoma
    InterventionPD-1 antibody
    PhasePhase 2
    Registry statusActive not recruiting

  • Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer

    NCT04498793 · start 2020-09

    Registered record
    Registry ID
    NCT04498793
    Conditions
    HER2-negative Breast Cancer
    Interventions
    Tislelizumab; Nab paclitaxel; Doxorubicin; Epirubicin; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-09
    Completion
    2022-12
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-negative Breast Cancer
    InterventionTislelizumab; Nab paclitaxel; Doxorubicin; Epirubicin +1 more
    PhasePhase 2
    Registry statusUnknown

  • A Benefit Population Atlas of nICT Versus nCT for LAGC

    NCT07098104 · start 2019-11-01

    Registered record
    Registry ID
    NCT07098104
    Conditions
    Gastric Cancer
    Interventions
    Immunotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-11-01
    Completion
    2025-05-01
    Enrolment
    291

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Cancer
    InterventionImmunotherapy
    PhaseNot recorded
    Registry statusCompleted

  • Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

    NCT03839823 · start 2019-02-25

    Registered record
    Registry ID
    NCT03839823
    Conditions
    Breast Cancer
    Interventions
    Docetaxel / Capecitabine; Capecitabine / Vinorelbine; Paclitaxel / Gemcitabine; Ribociclib; Letrozole OR Anastrozole; Goserelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-02-25
    Completion
    2023-05-10
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionDocetaxel / Capecitabine; Capecitabine / Vinorelbine; Paclitaxel / Gemcitabine; Ribociclib +2 more
    PhasePhase 2
    Registry statusCompleted

  • A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

    NCT03844256 · start 2019-01-07

    Registered record
    Registry ID
    NCT03844256
    Conditions
    Urinary Bladder Cancer; Invasive Bladder Cancer
    Interventions
    nivolumab 480mg; nivolumab 3mg/kg, ipilimumab 1mg/kg; nivolumab 1mg/kg, ipilimumab 3mg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2019-01-07
    Completion
    2026-07
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Bladder Cancer; Invasive Bladder Cancer
    Interventionnivolumab 480mg; nivolumab 3mg/kg, ipilimumab 1mg/kg; nivolumab 1mg/kg, ipilimumab 3mg/kg
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

    NCT02892123 · start 2016-09-30

    Registered record
    Registry ID
    NCT02892123
    Conditions
    HER2-expressing Cancers
    Interventions
    ZW25 (Zanidatamab); Paclitaxel; Capecitabine; Vinorelbine; Tucatinib; Tucatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-09-30
    Completion
    2024-10-31
    Enrolment
    279

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-expressing Cancers
    InterventionZW25 (Zanidatamab); Paclitaxel; Capecitabine; Vinorelbine +2 more
    PhasePhase 1
    Registry statusCompleted

  • A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer

    NCT02465593 · start 2015-06

    Registered record
    Registry ID
    NCT02465593
    Conditions
    Rectal Cancer
    Interventions
    PEP503; 5-fluorouracil; capecitabine; surgical resection; Radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2015-06
    Completion
    2021-07-28
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRectal Cancer
    InterventionPEP503; 5-fluorouracil; capecitabine; surgical resection +1 more
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

    NCT02004262 · start 2014-02-05

    Registered record
    Registry ID
    NCT02004262
    Conditions
    2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
    Interventions
    GVAX Pancreas Vaccine; CRS-207; Chemotherapy; cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-02-05
    Completion
    2016-08-23
    Enrolment
    303

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Condition2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
    InterventionGVAX Pancreas Vaccine; CRS-207; Chemotherapy; cyclophosphamide
    PhasePhase 2
    Registry statusCompleted